Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00962845 · ClinicalTrials.gov registry record · Early Phase 1
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
A Early Phase 1 study of Melanoma (Skin), sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00962845 is a Early Phase 1 study of Melanoma (Skin) that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 20 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00962845, a Early Phase 1 study of Melanoma (Skin), has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers. PURPOSE: This early phase I trial is studying hydroxychloroquine in patients with stage III or stage IV melanoma that can be removed by surgery.
Conditions Studied
Interventions
- DRUG hydroxychloroquine
Study Locations (1)
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-05-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00962845
The ClinicalTrials.gov registry entry for NCT00962845 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 1 intervention - of which hydroxychloroquine is the first listed.
NCT00962845 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00962845 about?
NCT00962845 is a clinical study titled "Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery". RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers. PURPOSE: This early phase I trial is studying hydroxychloroquine in patients with stage...
What is the current status of trial NCT00962845?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2010-09. Estimated completion is 2013-05-30.
What conditions does trial NCT00962845 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00962845?
The interventions under investigation include: hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT00962845?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00962845 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
COMPLETED · Early Phase 1
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
RECRUITING · NA
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.